H
Henning T. Mouridsen
Researcher at University of Copenhagen
Publications - 121
Citations - 16119
Henning T. Mouridsen is an academic researcher from University of Copenhagen. The author has contributed to research in topics: Breast cancer & Tamoxifen. The author has an hindex of 52, co-authored 120 publications receiving 15464 citations. Previous affiliations of Henning T. Mouridsen include Copenhagen University Hospital & The Breast Cancer Research Foundation.
Papers
More filters
Journal ArticleDOI
Influence of tumor location on breast cancer prognosis
TL;DR: It is found that survival is significantly better for women with a tumor in the upper lateral quadrant than tumors located elsewhere in the breast, and that a better lymph node staging procedure alone is unlikely to eliminate these survival differences.
Journal ArticleDOI
Adjuvant anthracycline in breast cancer. Improved outcome in premenopausal patients following substitution of methotrexate in the CMF Combination with epirubicin
Henning T. Mouridsen,Jørn Andersen,Martin Andersson,Per Dombernowsky,Bent Ejlertsen,Carsten Rose,P.G. Sørensen,Erik Sandberg,Andersen Kw,Maj-Britt Jensen,Nils O. Bengtson,Jonas Bergh,Bo Nordenskjöld +12 more
Journal ArticleDOI
Danish Breast Cancer Cooperative Group--DBCG: History, organization, and status of scientific achievements at 30-year anniversary
TL;DR: DBCG (Danish Breast Cancer Cooperative Group) constitutes a multidisciplinary organization established in 1975 by the Danish Surgical Society, which resulted in a reduction of relative risk of death amounting up to 20% and increased 5-year overall survival ascending from 60% to roughly 80%.
Journal ArticleDOI
HER2, TOP2A, and TIMP-1 and Responsiveness to Adjuvant Anthracycline-Containing Chemotherapy in High-Risk Breast Cancer Patients
Bent Ejlertsen,Maj-Britt Jensen,Kirsten Vang Nielsen,Eva Balslev,Birgitte Bruun Rasmussen,Gro Linno Willemoe,P. B. Hertel,Ann Knoop,Henning T. Mouridsen,Nils Brünner +9 more
TL;DR: The 2T profile is a more accurate predictor of incremental benefit from anthracycline-containing chemotherapy than HER2, TIMP-1, or TOP2A individually, and compared with these, 2T classifies a larger proportion of patients as sensitive to anthrACYclines.
Journal ArticleDOI
Carcinogenic Effects of Adjuvant Tamoxifen Treatment and Radiotherapy for Early Breast Cancer
TL;DR: With a median follow-up of 8 years, the incidence of tumours in the contralateral breast was similar among tamoxifen-treated, and non-treated high-risk patients even after adjusting for tumours arising within the first year.